AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11158747
Drug: Amprenavir (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifabutin (300 mg QD) for 10 days)
Trial: 11158747
Drug: Amprenavir (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir (1,200 mg twice a day for 4 days, followed by a washout period, then amprenavir plus rifampin (600 mg QD) for 4 days)
Trial: 9039154
Drug: Clonidine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.15 mg + captopril 6.25 mg
Trial: 9039154
Drug: Captopril 6.25
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 6.25 mg + placebo
Trial: 8316771
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Hydroxychloroquine + Dapsone)
Trial: 28214093
Drug: Education for
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education for Christian church leaders on scientific, religious, and cultural aspects of male circumcision (1-day seminar and bi-weekly meetings during the campaign)
Trial: 26196084
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms buccal misoprostol 3 hours preoperatively
Trial: 26196084
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral mifepristone during dilator placement
Trial: 23781269
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (5 days)
Trial: 17716735
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation of vitamin C (180 mg), vitamin E (30 mg), zinc (22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin (1 mg), and astaxanthin (4 mg) daily for 12 months (T-AMD group)
Trial: 14725410
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 6 months
Trial: 14725410
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 12 months
Trial: 14725410
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine, Avaxim 80 paediatric, given as a two-dose schedule with the second dose at 18 months
Trial: 10950003
Drug: Topical 10
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10 percent phenylephrine
Trial: 29223599
Drug: bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion hydrochloride sustained-release
Trial: 24796977
Drug: CHO7% (7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO7% (7% carbohydrate solution)
Trial: 24796977
Drug: lowCHO1.5% (1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lowCHO1.5% (1.5% carbohydrate solution)
Trial: 20177856
Drug: Intravenous carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous carbohydrate administration (glucose, magnesium, potassium)
Trial: 20177856
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate administration (specifically composed solution)
Trial: 19040000
Drug: Alen +
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alen + calcium group (n = 74) receiving Alen 10 mg once a day and castrate D 600 0.6 g once a day for 24 weeks
Trial: 19040000
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 66) receiving castrate D 600 0.6 g once a day for 24 weeks
Trial: 16330203
Drug: Intravenous replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous replacement fluid therapy (FT)
Trial: 14576555
Drug: 1 mug/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mug/ml fentanyl
Trial: 14576555
Drug: 0.0625% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% levobupivacaine and 1 mug/ml fentanyl
Trial: 8916625
Drug: Behavioral couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couples therapy (BCT)
Trial: 1602291
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (75 mg d-1, Group I, n = 4)
Trial: 1602291
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin (Group II, n = 5)
Trial: 27169837
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg quercetin‐3‐O‐glucoside
Trial: 27169837
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg quercetin‐3‐O‐glucoside
Trial: 27169837
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg quercetin‐3‐O‐glucoside
Trial: 27169837
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg quercetin‐3‐O‐glucoside
Trial: 27169837
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg quercetin‐3‐O‐glucoside (control)
Trial: 21049059
Drug: Paromomycin (PM)
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paromomycin (PM) at 15 mg/kg/day for 21 days
Trial: 21049059
Drug: Sodium stibogluconate
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate (SSG) at 20 mg/kg/day for 30 days
Trial: 21049059
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PM and SSG
Trial: 11788911
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin, fluorouracil (5‐FU), l‐leucovorin and interferon alpha2b (PFL‐IFN)
Trial: 10438259
Drug: Gemfibrozil (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (1200 mg per day)
Trial: 2147914
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ticlopidine twice daily
Trial: 2147914
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg aspirin every third day plus 75 mg dipyridamole three times daily
Trial: 2147914
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg xanthinol nicotinate three times daily
Trial: 6996931
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg dipyrone
Trial: 22428464
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg aspirin
Trial: 29036255
Drug: tavaborole 5%
RxNorm normalized name: TAVABOROLE 5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tavaborole 5% solution
Trial: 28472067
Drug: MVA85A vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA85A vaccine
Trial: 19332190
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration in patients with STEMI
Trial: 19332190
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration in patients with non-STEMI
Trial: 19332190
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration in patients with unstable angina
Trial: 19332190
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration in patients <65 years old receiving fibrinolytic therapy for STEMI
Trial: 19332190
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration in patients 65 to 74 years old receiving fibrinolytic therapy for STEMI
Trial: 19332190
Drug: Clopidogrel administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel administration in patients >75 years old receiving fibrinolytic therapy for STEMI
Trial: 15785163
Drug: Trandolapril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (angiotensin-converting enzyme inhibitor)
Trial: 15259398
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine polacrilex (2 mg)
Trial: 15259398
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitor (THA)
Trial: 7605022
Drug: Propofol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (target concentrations of 2, 4, or 6 micrograms/ml) with alfentanil (initial target concentration 50 ng/ml)
Trial: 7605022
Drug: Alfentanil (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (plasma concentrations increasing from 10 to 150 ng/ml)
Trial: 28428110
Drug: Peak flow
RxNorm normalized name: Peak Flow Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak flow categorized as 10 to 14.9 ml/s
Trial: 28428110
Drug: Peak flow
RxNorm normalized name: Peak Flow Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak flow categorized as less than 10 ml/s
Trial: 28428110
Drug: Peak flow
RxNorm normalized name: Peak Flow Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak flow categorized as 15 or greater ml/s
Trial: 28428110
Drug: Peak flow
RxNorm normalized name: Peak Flow Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak flow categorized as 10 to 14.9 ml/s (multivariable analysis)
Trial: 26168262
Drug: Family Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Focused Therapy for Clinical High‐Risk (FFT‐CHR), an 18-session intervention consisting of psychoeducation and training in communication and problem solving.
Trial: 26168262
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (FFT-CHR and control).
Trial: 23904409
Drug: Combined glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined glucocorticoid receptor/mineralocorticoid receptor stimulation with prednisolone
Trial: 21734467
Drug: Control (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (licensed quadrivalent meningococcal polysaccharide vaccine and hepatitis B vaccine)
Trial: 19388866
Drug: guaraná 75
RxNorm normalized name: GUARANA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guaraná 75 mg daily p.o.
Trial: 16626411
Drug: Fail-first algorithm
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fail-first algorithm on conventional antipsychotics (CON)
Trial: 16626411
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment requiring switching
Trial: 8936399
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of caffeine in coffee
Trial: 6854139
Drug: DMSO (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSO (30 ml, 70% solution)
Trial: 6854139
Drug: Sulindac (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (400 mg, orally)
Trial: 31820304
Drug: 10-mg orodispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg orodispersible tablet (DT1)
Trial: 31820304
Drug: 10-mg oral
RxNorm normalized name: rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-mg oral solution (SOL)
Trial: 31820304
Drug: 10-mg orodispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg orodispersible tablet without water (DT2dry)
Trial: 31820304
Drug: 10-mg orodispersible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg orodispersible tablet with water (DT2water, reference formulation)
Trial: 31663285
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once daily for 16 days)
Trial: 31663285
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg once daily for 16 days)
Trial: 20232605
Drug: Telephone counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone counseling along with a home telemonitoring scale and instructions to self‐weigh daily
Trial: 15998777
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (0.5 g, then 0.25 g, 6 wk each)
Trial: 15998777
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone starting with 0.1 g/d, then tapering the dose by 0.01 g/wk
Trial: 15998777
Drug: Intravenous glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucocorticoid therapy
Trial: 12776578
Drug: Ebastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine (10 mg once daily)
Trial: 12027065
Drug: Fexofenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (60 mg, twice daily)
Trial: 8603453
Drug: ThioTEPA 30
RxNorm normalized name: thiotepa 30 mg INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThioTEPA 30 mg/30 ml distilled water
Trial: 8603453
Drug: ThioTEPA 30
RxNorm normalized name: thiotepa 30 mg INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThioTEPA 30 mg/60 ml distilled water
Trial: 8603453
Drug: ThioTEPA 60
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ThioTEPA 60 mg/30 ml distilled water
Trial: 8603453
Drug: ThioTEPA 60
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ThioTEPA 60 mg/60 ml distilled water
Trial: 54579
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5000 units of sodium heparin every 12 hours for 5 days)
Trial: 54579
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin treatment
Trial: 31493728
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) anticoagulants (Vitamin K antagonists or Low Molecular Weight Heparin)
Trial: 25377272
Drug: CNI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNI therapy after belatacept withdrawal
Trial: 25377272
Drug: MMF monotherapy
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF monotherapy after belatacept withdrawal
Trial: 2526419
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (standard doses)
Trial: 2526419
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (third dose late, >7 months after first dose)
Trial: 2526419
Drug: Various schedules
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various schedules of dose timing (early/late second and third doses)
Trial: 11952465
Drug: 50 microgs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Trial: 11952465
Drug: 100 microgs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microgs of oral misoprostol, repeated every 4 h to a maximum of 5 doses.
Trial: 11952465
Drug: Preference for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preference for oral inducing agent if another induction is needed.
Trial: 23717118
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng (KRG) in CT genotype of G protein beta 3 gene
Trial: 23717118
Drug: Korean Red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean Red Ginseng (KRG) in Trp64/Arg genotype of beta 3 adrenergic receptor gene
Trial: 2203140
Drug: Multimodal tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal tumor therapy
Trial: 364910
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g/day) for 28 days
Trial: 21625183
Drug: Trastuzumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab treatment continued after diagnosis of BM
Trial: 16703336
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enamel matrix derivative and bioactive glass (group 2, n=13)
Trial: 12658483
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) 0.3 IU/kg/day subcutaneously from day 3 before operation until day 7 after operation
Trial: 12658483
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH)
Trial: 12658483
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) and Placebo
Trial: 10955339
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) for RA
Trial: 10955339
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) for OA
Trial: 1431344
Drug: Anti-CEA monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CEA monoclonal antibody (F023C5) radioimmunoscintigraphy (RIS)
Trial: 3855601
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 in 1 mg dose
Trial: 3855601
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 in 2 mg dose
Trial: 3855601
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 in 3 mg dose
Trial: 3855601
Drug: Placebo (vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vaginal triacetin gel)
Trial: 22045925
Drug: Telemonitoring (TM)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Telemonitoring (TM) for 6 months, measuring body weight, blood pressure, and heart rate daily with electronic devices.
Trial: 20101186
Drug: Valproate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valproate (20 mg/kg/day)
Trial: 20101186
Drug: Lithium (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (800 mg/day)
Trial: 18037769
Drug: Pycnogenol (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (180 mg/day)
Trial: 10392392
Drug: 1450 T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1450 T lead (steroid group)
Trial: 1824736
Drug: mannitol (15‐g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mannitol (15‐g bolus followed by 15% infusion mixed in 75 mmol/L saline at 100 mL/h for 1 hour)
Trial: 1824736
Drug: saline (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (equal volume of 75 mmol/L saline, intravenously)
Trial: 31345387
Drug: reduced-dose chemoradiation
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: reduced-dose chemoradiation (rdCRT) with 5600 cGy and weekly carboplatin
Trial: 31345387
Drug: standard-dose chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-dose chemoradiotherapy (sdCRT) with 7000 cGy
Trial: 27707550
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab (RBZ)
Trial: 27707550
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab (RBZ)
Trial: 21914410
Drug: Intrathecal immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal immunoglobulin in addition to standard treatment (group A)